Optofluid Technologies — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Optofluid Technologies is a Copenhagen-based developer of optical sensors for real-time monitoring of dialysis treatment quality. Its core technology, Multicomponent Monitoring (MCM), uses a combination of optical methods to measure protein-bound and middle molecule toxins, moving beyond standard urea measurement. The company, founded in 2010, is backed by significant EU research grants and holds an extensive international patent portfolio. Its solution targets a critical data gap in current dialysis care, with the potential to personalize treatment and improve patient survival.

NephrologyChronic Kidney Disease

Technology Platform

Multicomponent Monitoring (MCM) sensor using a combination of optical methods (e.g., UV absorbance, fluorescence) to perform real-time, on-line analysis of uremic toxins (including protein-bound and middle molecules) in dialysis fluid.

Opportunities

The large and growing global dialysis patient population creates a substantial addressable market for a device that improves treatment personalization and outcomes.

The shift towards value-based care and home dialysis increases demand for real-time monitoring tools.

The technology also has potential applications in other extracorporeal therapies and as a component in future implantable artificial kidneys.

Risk Factors

Key risks include the need for robust clinical validation and regulatory approval (CE/FDA) for a novel medical device.

Commercialization is challenging in a market dominated by large dialysis equipment OEMs, requiring successful partnerships or a costly direct sales effort.

Establishing reimbursement for the new monitoring capability is another critical hurdle.

Competitive Landscape

Competition includes traditional lab-based testing services and limited on-line monitors that primarily measure only urea or UV-absorbance at a single wavelength. Optofluid's key differentiation is its patented multi-optical method approach designed to specifically measure protein-bound and middle molecules, a segment with limited direct competitors. However, large dialysis machine manufacturers could develop similar capabilities in-house.

More companies in Europe - Other →